BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32962455)

  • 1. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
    Pradhan RR; Nepal G; Mandal S
    Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
    Bettiol A; Urban ML; Dagna L; Cottin V; Franceschini F; Del Giacco S; Schiavon F; Neumann T; Lopalco G; Novikov P; Baldini C; Lombardi C; Berti A; Alberici F; Folci M; Negrini S; Sinico RA; Quartuccio L; Lunardi C; Parronchi P; Moosig F; Espígol-Frigolé G; Schroeder J; Kernder AL; Monti S; Silvagni E; Crimi C; Cinetto F; Fraticelli P; Roccatello D; Vacca A; Mohammad AJ; Hellmich B; Samson M; Bargagli E; Cohen Tervaert JW; Ribi C; Fiori D; Bello F; Fagni F; Moroni L; Ramirez GA; Nasser M; Marvisi C; Toniati P; Firinu D; Padoan R; Egan A; Seeliger B; Iannone F; Salvarani C; Jayne D; Prisco D; Vaglio A; Emmi G;
    Arthritis Rheumatol; 2022 Feb; 74(2):295-306. PubMed ID: 34347947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
    Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
    J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
    Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
    Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    Ennis D; Lee JK; Pagnoux C
    Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
    Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
    Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.
    Molina B; Padoan R; Urban ML; Novikov P; Caminati M; Taillé C; Néel A; Bouillet L; Fraticelli P; Schleinitz N; Christides C; Moi L; Godeau B; Knight A; Schroeder JW; Marchand-Adam S; Gil H; Cottin V; Durel CA; Gelain E; Lerais B; Ruivard M; Groh M; Samson M; Moroni L; Thiel J; Kernder A; Cohen Tervaert JW; Costanzo G; Folci M; Rizzello S; Cohen P; Emmi G; Terrier B
    Ann Rheum Dis; 2023 Dec; 82(12):1587-1593. PubMed ID: 37734881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
    Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
    J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
    Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
    Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
    Doubelt I; Pulenzas N; Carette S; Pagnoux C;
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
    Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
    Yamane T; Hashiramoto A
    Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
    Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis.
    Higashitani K; Yoshimi R; Sato Y; Watanabe T; Ihata A
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):87-92. PubMed ID: 34473835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
    Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
    J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Nara M; Saito M; Abe F; Komatsuda A; Wakui H; Takahashi N
    Intern Med; 2019 Dec; 58(24):3583-3587. PubMed ID: 31391393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
    Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
    Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
    Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.